Prognostic Value of Plasma Fibrinolysis Activation Markers in Cardiovascular Disease

Journal of the American College of Cardiology

Volumn 55, Issue 24, 2010, Pages 2701-2709

  Gorog, Diana A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

biomarker; cardiovascular; D dimer; fibrinolysis; lipoprotein (a); PAI 1; TPA

Indexed keywords

ALPHA 2 ANTIPLASMIN; BIOLOGICAL MARKER; D DIMER; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADVERSE OUTCOME; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ENZYME BLOOD LEVEL; FIBRINOLYSIS; HUMAN; IMMUNOASSAY; LIPOPROTEIN BLOOD LEVEL; MEASUREMENT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; LIPOPROTEIN(A); PROGNOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77953085605     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.11.095     Document Type: Review

References (99)

1. Lijnen H.R., and Collen D. Impaired fibrinolysis and the risk for coronary heart disease. Circulation 94 (1996) 2052-2054
2. Hoffmeister H.M., Heller W., and Seipel L. Activation markers of coagulation and fibrinolysis: alterations and predictive value in acute coronary syndromes. Thromb Haemost 82 Suppl 1 (1999) 76-79
3. Buja L.M., Hillis L.D., Petty C.S., and Willerson J.T. The role of coronary arterial spasm in ischemic heart disease. Arch Pathol Lab Med 105 (1981) 221-226
4. Harris P. A theory concerning the course of events in angina and myocardial infarction. Eur J Cardiol 3 (1975) 157-163
5. Davies M.J., and Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 310 (1984) 1137-1140
6. Zingerman L.S., Golikov A.P., Topchiian G.S., Galakina I.E., and Zvereva T.V. [The possibility of spontaneous lysis of a coronary thrombus in patients with acute myocardial infarct]. Kardiologiia 28 (1988) 24-28
7. Chan K.L., Davies R.A., and Chambers R.J. Coronary thrombosis and subsequent lysis after a marathon. J Am Coll Cardiol 4 (1984) 1322-1325
8. Keller H.M., Schubiger O., Turina M., and Zumstein B. Disappearing obstructions in extracranial cerebral arteries. Acta Neurol Belg 80 (1980) 19-29
9. Seibert C.E., and Swanson W.B. Lysis of thrombus in internal carotid artery in the neck. Report of a case. Acta Radiol Suppl 347 (1976) 271-275
10. Weiner M.A., Sniderman K.W., Sos T.A., Saddekni S., and Silane M. Two cases of spontaneous lysis of arterial thrombi. Cardiovasc Intervent Radiol 7 (1984) 24-27
11. Swan H.J. Acute myocardial infarction: a failure of timely, spontaneous thrombolysis. J Am Coll Cardiol 13 (1989) 1435-1437
12. Christian T.F., Milavetz J.J., Miller T.D., Clements I.P., Holmes D.R., and Gibbons R.J. Prevalence of spontaneous reperfusion and associated myocardial salvage in patients with acute myocardial infarction. Am Heart J 135 (1998) 421-427
13. Bainey K.R., Fu Y., Wagner G.S., et al. Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. Am Heart J 156 (2008) 248-255
14. Fefer P., Hod H., Hammerman H., Boyko V., Behar S., and Matetzky S. Relation of clinically defined spontaneous reperfusion to outcome in ST-elevation myocardial infarction. Am J Cardiol 103 (2009) 149-153
15. Fornitz G.G., Nielsen P., Amtorp O., et al. Impaired fibrinolysis determines the outcome of percutaneus transluminal coronary angioplasty (PTCA). Eur J Clin Invest 31 (2001) 586-592
16. Osterlund B., Jern S., Jern C., et al. Impaired myocardial t-PA release in patients with coronary artery disease. Acta Anaesthesiol Scand 52 (2008) 1375-1384
17. Guimaraes A.H., de Bruijne E.L., Lisman T., et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 145 (2009) 115-120
18. Rijken D.C., and Lijnen H.R. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 7 (2009) 4-13
19. Zorio E., Gilabert-Estelles J., Espana F., Ramon L.A., Cosin R., and Estelles A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 15 (2008) 923-929
20. Adams S.A., Kelly S.L., Kirsch R.E., Robson S.C., and Shephard E.G. Role of neutrophil membrane proteases in fibrin degradation. Blood Coagul Fibrinolysis 6 (1995) 693-702
21. Undas A., Szuldrzynski K., Stepien E., et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 196 (2008) 551-557
22. Nordenhem A., and Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest 58 (1998) 475-483
23. Wiman B. Predictive value of fibrinolytic factors in coronary heart disease. Scand J Clin Lab Invest Suppl 230 (1999) 23-31
24. May M., Lawlor D.A., Patel R., Rumley A., Lowe G., and Ebrahim S. Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study. Eur J Cardiovasc Prev Rehabil 14 (2007) 638-645
25. Gram J., Bladbjerg E.M., Moller L., Sjol A., and Jespersen J. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J Intern Med 247 (2000) 205-212
26. Pradhan A.D., LaCroix A.Z., Langer R.D., et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 110 (2004) 292-300
27. Smith F.B., Fowkes F.G., Rumley A., Lee A.J., Lowe G.D., and Hau C.M. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J 21 (2000) 1607-1613
28. Kinlay S., Schwartz G.G., Olsson A.G., et al. Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study. Atherosclerosis 206 (2009) 551-555
29. Lee C.W., Ahn J.M., Park D.W., et al. Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty. Atherosclerosis 196 (2008) 327-332
30. Soeki T., Tamura Y., Shinohara H., Sakabe K., Onose Y., and Fukuda N. Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death. Int J Cardiol 85 (2002) 277-283
31. Smith A., Patterson C., Yarnell J., Rumley A., Ben-Shlomo Y., and Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke?. The Caerphilly Study. Circulation 112 (2005) 3080-3087
32. Takazoe K., Ogawa H., Yasue H., et al. Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris. Ann Med 33 (2001) 206-212
33. Akkus M.N., Polat G., Yurtdas M., et al. Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. Int Heart J 50 (2009) 33-45
34. Marcucci R., Brogi D., Sofi F., et al. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart 92 (2006) 377-381
35. Onalan O., Balta G., Oto A., et al. Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease. J Thromb Thrombolysis 26 (2008) 211-217
36. Nordenhem A., Leander K., Hallqvist J., de Faire U., Sten-Linder M., and Wiman B. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. Thromb Res 116 (2005) 223-232
37. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639
38. Itakura H., Sobel B.E., Boothroyd D., et al. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?. Am Heart J 154 (2007) 1059-1064
39. Pineda J., Marin F., Marco P., et al. Premature coronary artery disease in young (age <45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol 136 (2009) 222-225
40. Sargento L., Saldanha C., Monteiro J., Perdigao C., and Silva J.M. Long-term prognostic value of protein C activity, erythrocyte aggregation and membrane fluidity in transmural myocardial infarction. Thromb Haemost 94 (2005) 380-388
41. Cushman M., Lemaitre R.N., Kuller L.H., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19 (1999) 493-498
42. Alehagen U., Dahlstrom U., and Lindahl T.L. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 92 (2004) 1250-1258
43. Folsom A.R., Delaney J.A., Lutsey P.L., et al. Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality. Am J Hematol 84 (2009) 349-353
44. Tello-Montoliu A., Marin F., Roldan V., et al. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med 262 (2007) 651-658
45. Prisco D., Fedi S., Antonucci E., et al. Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 104 (2001) 181-186
46. Marcucci R., Gori A.M., Giannotti F., et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 4 (2006) 1017-1022
47. Bayes-Genis A., Mateo J., Santalo M., et al. D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am Heart J 140 (2000) 379-384
48. Tokita Y., Kusama Y., Kodani E., et al. Utility of rapid D-dimer measurement for screening of acute cardiovascular disease in the emergency setting. J Cardiol 53 (2009) 334-340
49. Brugger-Andersen T., Ponitz V., Staines H., Grundt H., Hetland O., and Nilsen D.W. The prognostic utility of D-dimer and fibrin monomer at long-term follow-up after hospitalization with coronary chest pain. Blood Coagul Fibrinolysis 19 (2008) 701-707
50. McCann C.J., Glover B.M., Menown I.B., et al. Investigation of a multimarker approach to the initial assessment of patients with acute chest pain. Adv Ther 26 (2009) 531-534
51. Redondo M., Carroll V.A., Mauron T., et al. Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin-alpha2-antiplasmin complex is an independent predictor of coronary re-events. Blood Coagul Fibrinolysis 12 (2001) 17-24
52. Morange P.E., Bickel C., Nicaud V., et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol 26 (2006) 2793-2799
53. Schoebel F.C., Peters A.J., Kreis I., Gradaus F., Heins M., and Jax T.W. Relevance of hemostasis on restenosis in clinically stable patients undergoing elective PTCA. Thromb Res 122 (2008) 229-236
54. Juhan-Vague I., Morange P.E., Aubert H., et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22 (2002) 867-873
55. Meltzer M.E., Doggen C.J., de Groot P.G., Meijers J.C., Rosendaal F.R., and Lisman T. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 94 (2009) 811-818
56. de Bruijne E.L., Gils A., Guimaraes A.H., et al. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. J Thromb Haemost 7 (2009) 919-927
57. Segev A., Hegele R.A., Lau H.K., et al. Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions. Thromb Res 114 (2004) 137-141
58. Tregouet D.A., Schnabel R., Alessi M.C., et al. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 7 (2009) 49-57
59. Schroeder V., Chatterjee T., Mehta H., et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 88 (2002) 1020-1025
60. Zorio E., Castello R., Falco C., et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 122 (2003) 958-965
61. Lau H.K., Segev A., Hegele R.A., et al. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thromb Haemost 90 (2003) 1187-1191
62. Folkeringa N., Coppens M., Veeger N.J., et al. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost 100 (2008) 38-44
63. Paola C.A., Antonucci E., Alessandrello L.A., et al. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 118 (2006) 495-500
64. Gaw A., Murray H.M., and Brown E.A. Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER). Atherosclerosis 180 (2005) 381-388
65. Kim J.W., Seo H.S., Suh S.Y., et al. Relationship between lipoprotein(a) and spontaneous recanalization of infarct-related arteries in the early phase of acute myocardial infarction. Clin Cardiol 31 (2008) 211-216
66. Corsetti J.P., Ryan D., Rainwater D.L., et al. Lp(a) and risk of recurrent cardiac events in obese postinfarction patients. Obesity (Silver Spring) 16 (2008) 2717-2722
67. Klein J.H., Hegele R.A., Hackam D.G., Koschinsky M.L., Huff M.W., and Spence J.D. Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol 28 (2008) 1851-1856
68. Sagastagoitia J.D., Vacas M., Saez Y., et al. [Lipoprotein (a), D-Dimer and apolipoprotein A1 as markers of presence and severity of coronary disease]. Med Clin (Barc) 132 (2009) 689-694
69. Sagastagoitia J.D., Vacas M., Saez Y., et al. [Predictive value of lipoprotein (a) and apolipoprotein A1 in patients with angiographycally evaluated coronary stenosis]. Med Clin (Barc) 128 (2007) 601-604
70. Miner S.E., Hegele R.A., Sparkes J., et al. Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am Heart J 140 (2000) 272-278
71. Erqou S., Kaptoge S., Perry P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 (2009) 412-423
72. Wang J.J., Zhang C.N., Meng Y., Han A.Z., Gong J.B., and Li K. Elevated concentrations of oxidized lipoprotein(a) are associated with the presence and severity of acute coronary syndromes. Clin Chim Acta 408 (2009) 79-82
73. Mackness M., and Hughes E. Variability in the measurement of lipoprotein(a) in the British Isles. Ann Clin Biochem 46 (2009) 311-315
74. Bach-Gansmo E.T., Halvorsen S., Godal H.C., and Skjonsberg O.H. D-dimers are degraded by human neutrophil elastase. Thromb Res 82 (1996) 177-186
75. de Lau L.M., Cheung E.Y., Kluft C., et al. Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke. Br J Haematol 143 (2008) 734-737
76. Torr-Brown S.R., and Sobel B.E. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 72 (1993) 413-421
77. Simpson A.J., Booth N.A., Moore N.R., and Bennett B. The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease. Br J Haematol 75 (1990) 543-548
78. Soeki T., Tamura Y., Fukuda N., and Ito S. Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction. Jpn Circ J 64 (2000) 547-553
79. Katsaros K.M., Kastl S.P., Huber K., et al. Clopidogrel pretreatment abolishes increase of PAI-1 after coronary stent implantation. Thromb Res 123 (2008) 79-84
80. Bouma B.N., and Mosnier L.O. Thrombin activatable fibrinolysis inhibitor (TAFI)-how does thrombin regulate fibrinolysis?. Ann Med 38 (2006) 378-388
81. Semeraro F., Ammollo C.T., Semeraro N., and Colucci M. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica 94 (2009) 819-826
82. Declerck P.J., and Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res Suppl 10 (1990) 3-9
83. Marx P.F., Plug T., Havik S.R., Morgelin M., and Meijers J.C. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?. J Thromb Haemost 7 (2009) 445-452
84. Anand K., Pallares I., Valnickova Z., et al. The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa. J Biol Chem 283 (2008) 29416-29423
85. Isordia-Salas I., Leanos-Miranda A., Sainz I.M., Reyes-Maldonado E., and Borrayo-Sanchez G. Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients. Rev Esp Cardiol 62 (2009) 365-372
86. Su S., Chen S., Zhao J., et al. Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease. Arterioscler Thromb Vasc Biol 26 (2006) 948-954
87. Sibbing D., von Beckerath O., von Beckerath N., et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. Blood Coagul Fibrinolysis 16 (2005) 511-515
88. Ding J., Nicklas B.J., Fallin M.D., et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 152 (2006) 1109-1115
89. van der Krabben M.D., Rosendaal F.R., van der Bom J.G., and Doggen C.J. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost 6 (2008) 720-725
90. Collet J.P., Allali Y., Lesty C., et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26 (2006) 2567-2573
91. He S., Bark N., Wang H., Svensson J., and Blombäck M. Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis. J Cardiovasc Pharmacol 53 (2009) 24-29
92. Taylor Jr. F.B., and Lockhart M.S. Whole blood clot lysis: in vitro modulation by activated protein C. Thromb Res 37 (1985) 639-649
93. Yamamoto J., Yamashita T., Ikarugi H., et al. Gorog Thrombosis Test: a global in-vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis 14 (2003) 31-39
94. Goldenberg N.A., Hathaway W.E., Jacobson L., and Manco-Johnson M.J. A new global assay of coagulation and fibrinolysis. Thromb Res 116 (2005) 345-356
95. He S., Zhu K., Skeppholm M., et al. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thromb Haemost 98 (2007) 871-882
96. Stief T.W., Frohlich S., and Renz H. Determination of the global fibrinolytic state. Blood Coagul Fibrinolysis 18 (2007) 479-487
97. Stief T.W. Singlet oxygen enhances intrinsic thrombolysis: the intrinsic oxidative clot lysis assay (INOXCLA). Clin Appl Thromb Hemost 13 (2007) 369-383
98. Rijken D.C., Hoegee-de N.E., Jie A.F., Atsma D.E., Schalij M.J., and Nieuwenhuizen W. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost 6 (2008) 151-157
99. Cellai A.P., Lami D., Magi A., et al. Assessment of fibrinolytic activity by measuring the lysis time of a tissue factor-induced clot: a feasibility evaluation. Clin Appl Thromb Hemost (2008 Dec 30) [E-pub ahead of print]